Revenue for the quarter ended December 27, 2025 reached $339 million, a 2.7% decline from the $348.54 million reported in the same period last year. The drop is largely attributable to the divestiture of the Whole Blood product line in January 2025, which removed a high‑volume, lower‑margin segment from the company’s portfolio. Despite the decline, revenue still surpassed the consensus estimate of $334.2 million by $4.8 million, reflecting stronger performance in the plasma and hospital segments. Plasma revenue grew 3.5% to $138.9 million, while hospital revenue held steady at $143.5 million, offsetting the 19.6% decline in the blood center segment.
Adjusted earnings per share for the quarter were $1.31, beating the consensus estimate of $1.27 by $0.04, or 3.15%. The beat was driven by disciplined cost management and a favorable product mix shift toward higher‑margin plasma and hospital technologies. Operating margin expanded to 19.9% from 16.9% YoY, supported by a 4.2‑percentage‑point increase in gross margin to 59.7% as the company’s focus on innovation and higher‑margin products paid off.
Gross margin climbed to 59.7% from 55.5% in the prior year, a 4.2‑percentage‑point gain that underscores the effectiveness of Haemonetics’ portfolio rationalization and pricing strategy. The margin improvement is largely due to the increased contribution of plasma products, which carry higher margins, and the successful integration of recent acquisitions that have added value‑added capabilities to the company’s interventional technology line.
Management raised its full‑year 2026 guidance. Adjusted EPS is now projected at $4.90 to $5.00, up from the previous $4.80 to $5.00 range, while free cash flow guidance increased to $200 million–$220 million from $170 million–$210 million. Revenue guidance now anticipates a 1%–3% decline versus the prior 1%–4% forecast, and organic revenue growth is expected to be 0%–2% compared to the previous –1%–2% range. The company maintains its operating‑margin target of 26%–27%, signaling confidence in sustaining profitability despite the top‑line slowdown.
CEO Chris Simon highlighted that the core businesses—plasma collection and blood management technologies—continue to drive performance, while the company is focused on rebuilding momentum in its interventional technologies segment. He noted preparations for the U.S. launch of PerQseal Elite and expressed confidence that the company will finish the fiscal year strong, delivering on its long‑term growth and value‑creation objectives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.